These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 18006878)
1. Priming and stimulation of hepatitis C virus-specific CD4+ and CD8+ T cells against HCV antigens NS4, NS5a or NS5b from HCV-naive individuals: implications for prophylactic vaccine. Li W; Krishnadas DK; Kumar R; Tyrrell DL; Agrawal B Int Immunol; 2008 Jan; 20(1):89-104. PubMed ID: 18006878 [TBL] [Abstract][Full Text] [Related]
2. Induction of primary human T cell responses against hepatitis C virus-derived antigens NS3 or core by autologous dendritic cells expressing hepatitis C virus antigens: potential for vaccine and immunotherapy. Li W; Krishnadas DK; Li J; Tyrrell DL; Agrawal B J Immunol; 2006 May; 176(10):6065-75. PubMed ID: 16670315 [TBL] [Abstract][Full Text] [Related]
3. The functional evaluation of dendritic cell vaccines based on different hepatitis C virus nonstructural genes. Tian Y; Zhang HH; Wei L; Du SC; Chen HS; Fei R; Liu F Viral Immunol; 2007 Dec; 20(4):553-61. PubMed ID: 18158729 [TBL] [Abstract][Full Text] [Related]
4. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Swadling L; Capone S; Antrobus RD; Brown A; Richardson R; Newell EW; Halliday J; Kelly C; Bowen D; Fergusson J; Kurioka A; Ammendola V; Del Sorbo M; Grazioli F; Esposito ML; Siani L; Traboni C; Hill A; Colloca S; Davis M; Nicosia A; Cortese R; Folgori A; Klenerman P; Barnes E Sci Transl Med; 2014 Nov; 6(261):261ra153. PubMed ID: 25378645 [TBL] [Abstract][Full Text] [Related]
5. In vitro activation and differentiation of naïve CD4+ and CD8+ T cells into HCV core- and NS3-specific armed effector cells: a new role for CD4+ T cells. Krishnadas DK; Li W; Kumar R; Tyrrell LJ; Agrawal B Cell Immunol; 2009; 259(2):141-9. PubMed ID: 19616202 [TBL] [Abstract][Full Text] [Related]
6. Recombinant adenoviral vector expressing HCV NS4 induces protective immune responses in a mouse model of Vaccinia-HCV virus infection: a dose and route conundrum. Singh S; Vedi S; Li W; Samrat SK; Kumar R; Agrawal B Vaccine; 2014 May; 32(23):2712-21. PubMed ID: 24631092 [TBL] [Abstract][Full Text] [Related]
7. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV. Marín MQ; Pérez P; Ljungberg K; Sorzano CÓS; Gómez CE; Liljeström P; Esteban M; García-Arriaza J J Virol; 2019 Apr; 93(7):. PubMed ID: 30674625 [TBL] [Abstract][Full Text] [Related]
8. A synthetic codon-optimized hepatitis C virus nonstructural 5A DNA vaccine primes polyfunctional CD8+ T cell responses in wild-type and NS5A-transgenic mice. Holmström F; Pasetto A; Nähr V; Brass A; Kriegs M; Hildt E; Broderick KE; Chen M; Ahlén G; Frelin L J Immunol; 2013 Feb; 190(3):1113-24. PubMed ID: 23284053 [TBL] [Abstract][Full Text] [Related]
9. Strong HCV NS3/4a, NS4b, NS5a, NS5b-specific cellular immune responses induced in Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Latimer B; Toporovski R; Yan J; Pankhong P; Morrow MP; Khan AS; Sardesai NY; Welles SL; Jacobson JM; Weiner DB; Kutzler MA Hum Vaccin Immunother; 2014; 10(8):2357-65. PubMed ID: 25424943 [TBL] [Abstract][Full Text] [Related]
10. Strategies for loading dendritic cells with hepatitis C NS5a antigen and inducing protective immunity. Yu H; Babiuk LA; van Drunen Littel-van den Hurk S J Viral Hepat; 2008 Jun; 15(6):459-70. PubMed ID: 18221298 [TBL] [Abstract][Full Text] [Related]
13. Induction of Genotype Cross-Reactive, Hepatitis C Virus-Specific, Cell-Mediated Immunity in DNA-Vaccinated Mice. Wijesundara DK; Gummow J; Li Y; Yu W; Quah BJ; Ranasinghe C; Torresi J; Gowans EJ; Grubor-Bauk B J Virol; 2018 Apr; 92(8):. PubMed ID: 29437963 [TBL] [Abstract][Full Text] [Related]
14. [Comparative analysis of the immune response to DNA constructions encoding hepatitis C virus nonstructural proteins]. Masalova OV; Lesnova EI; Ivanov AV; Pichugin AV; Permiakova KIu; Smirnova OA; Tynitskaia VL; Ulanova TI; Burkov AN; Kochetkov SN; Ataullakhanov RI; Kushch AA Vopr Virusol; 2013; 58(2):21-8. PubMed ID: 23785766 [TBL] [Abstract][Full Text] [Related]
15. Identification of drug resistance and immune-driven variations in hepatitis C virus (HCV) NS3/4A, NS5A and NS5B regions reveals a new approach toward personalized medicine. Ikram A; Obaid A; Awan FM; Hanif R; Naz A; Paracha RZ; Ali A; Janjua HA Antiviral Res; 2017 Jan; 137():112-124. PubMed ID: 27984060 [TBL] [Abstract][Full Text] [Related]
16. Single-Dose Vaccination with a Hepatotropic Adeno-associated Virus Efficiently Localizes T Cell Immunity in the Liver with the Potential To Confer Rapid Protection against Hepatitis C Virus. Mekonnen ZA; Grubor-Bauk B; English K; Leung P; Masavuli MG; Shrestha AC; Bertolino P; Bowen DG; Lloyd AR; Gowans EJ; Wijesundara DK J Virol; 2019 Oct; 93(19):. PubMed ID: 31292249 [TBL] [Abstract][Full Text] [Related]
17. Priming with two DNA vaccines expressing hepatitis C virus NS3 protein targeting dendritic cells elicits superior heterologous protective potential in mice. Guan J; Deng Y; Chen H; Yin X; Yang Y; Tan W Arch Virol; 2015 Oct; 160(10):2517-24. PubMed ID: 26215441 [TBL] [Abstract][Full Text] [Related]